Sekisui is investing £14.4 million in its biopharma CDMO business aimed at cGMP microbial capacity expansion at the existing site in Maidstone, Kent to be completed by 2H22. This investment follows the investment of $1.9 million in its new Bioprocess Innovation Centre, completed in October 2019, and is part of a long-term investment strategy to grow its share of the microbial biopharma CDMO market. Previously part of Genzyme Corp., Sekisui Diagnostics’ Enzyme business launched its microbial b...